COVID-19 and Omics Technologies is a comprehensive, integrative assessment of recent information and knowledge collected on SARS-CoV-2 and COVID-19 during the pandemic based on omics technologies. It demonstrates how omics technologies could better investigate the infectious disease and propose solutions to the current concerns.
The value of multi-omics technologies in understanding disease etiology and host response, discovering infection biomarkers and illness prediction, identifying vaccine candidates, discovering therapeutic targets, and tracing pathogen evolution is discussed in this book. These factors combine to make it a valuable resource to enhance understanding of both Omics technology and COVID-19 as a disease. The book covers the most recent understanding of COVID-19 and the applications of cutting-edge studies, making it accessible to a large multidisciplinary readership.
The book explains how high-throughput technologies and systems biology might assist to solve the pandemic's challenges and deconstruct and appreciate the substantial contributions that omics technologies have made in predicting the path of this unforeseeable pandemic.
Features:
- In-depth summary of clinical presentation, epidemiological impact, and long-term sequelae of COVID-19 pandemic.
- A systematic overview of omics-based approaches to the study of COVID-19 biology.
- Recent research results and some pointers to future advancements in methodologies used.
- Detailed examples from recent studies on COVID-19 encompassing different omics methodologies.
- A detailed description of methodologies and notes on the applications of state-of-the-art technologies.
This book is intended for scientists who need to understand the biology of COVID-19 from the perspective of omics investigations, as well as researchers who want to employ omics-based technologies in disease biology.
About the Author: Prof. Sanjeeva Srivastava is a professor and the group leader of the Proteomics Laboratory at the Department of Biosciences and Bioengineering at the Indian Institute of Technology, Bombay. High-throughput proteomics, protein microarrays, and mass spectrometry are among his specialties. He has implemented ground-breaking AI-driven data analytics on big biological datasets. He has been at the forefront of biomedical research based on big data. His group's current research focuses on the development of clinical biomarkers for infectious diseases and malignancies. His group also pioneered therapeutic target identification efforts and decoded protein interaction networks in human illnesses like gliomas and contagious diseases like COVID-19 and malaria. His group has developed reliable diagnostic biomarkers and described the pathophysiology of severe malaria (falciparum and vivax) and COVID-19, especially the underlying mechanisms that lead to the development of severe sequelae.
Dr. Srivastava is an active contributor to global proteomics research and development. He serves on the Executive Committee of Human Proteome Organization (HUPO) and Proteomics Society, India (PSI). He has more than 125 publications from his work as an independent researcher at IIT Bombay. To date, he has filed 15 patents that include biomarkers for various types of cancers, infectious diseases like malaria, leptospirosis, COVID-19, and method improvement in uncharted territories such as fish and plant proteomics.
